Uit de Q3 conference call van FAGRON
Roderick Verhelst: Good morning, and thank you for taking my questions. Most of them have already been answered but I just wanted to dive a little bit deeper into the 10 million costs you’re going to cut. How is this going to spread out over different divisions? And how do you see the cost-cutting going forward in 2016, and also related to that, your margins, you now guide for margins of 22% - do you see margins remaining at this level for the coming years, or do you think, if you can cut costs further going forward? Then secondly you have of course the news that AmerisourceBergen has bought Pharmedium; can you maybe indicate if this one of the parties looking into you, and what do you think of this acquisition? Thank you.
Jan Peeters: Roderick, your first question about the cost cutting exercise, this has been initiated in July, and as we stated, the full-year impact will be ten million, and that will occur as of July going forward. It’s a company-wide, so we will not provide any more details on which divisions will be impacted for how much. For margins on 2016, we don’t give, we don’t provide and guidance yet for 2016, and on Pharmedium, we have seen that acquisition, obviously, with great interest, and I think our conclusion is that this underpins that the market, which we invested in already since January ’14, let’s say the sterile outsourcing 503B market in the US, is very promising, given the multiple which has been paid for PharMEDium, I think just underpins the upside potential of that market, and that for us is the most important message out of this trade sale which we have seen this week.
Roderick Verhelst: Okay, thank you.